Predictions That Hospital M and A Will Pick Up in 2024
The article says that hospital mergers and acquisitions will pick up in 2024. A number of factors are cited, including financial pressures and outside forces. Deals were robust before the COVID pandemic and then collapsed. They picked up in 2023 and will grow more in 2024. They won’t hit pre-pandemic levels though. New merger guidelines and the Biden administration’s anti-trust views could be a wild card and impact the ongoing recovery of M and A.
(Article may require a subscription.)
#hospitals #mergers #acquisitions
Threats From FTC Push Brand Drug Makers To Change Orange Book Entries
The Federal Trade Commission’s (FTC) threats to come after brand drug makers who misrepresent patents in the Food and Drug Administration’s (FDA) Orange Book are leading several drug makers to change or pull patent entries. It is good news as these disclosures help determine whether a generic maker will make investments in drugs as brands come close to patent expiration. It has been one of the things brand drug makers use to squelch generic introduction.
#drugpricing #ftc #fda #branddrugmakers #brands #generics
ICER Reports Drug Price Increases Occur With No New Evidence Of Health Benefits
Important report by the drug price watchdog Institute for Clinical and Economic Review’s (ICER) about the fact that drug price hikes occur with no new evidence of health benefits. Of course PhRMA discounts all this, but price hikes meant spending went up by $1.3 billion for just eight drugs in 2022. The ICER says these hikes are not backed by clinical data. Humira alone meant a $386 million increase. It topped the list. Thankfully, three of the eight drugs on the list are subject to the new Medicare drug price negotiations. Further, there is some hope that a biosimilar to Humira will begin to gain acceptance over time in the market. But Humira’s maker is trying to stop this.
(Article may require a subscription.)
#drugpricing #ira #icer #branddrugmakers
Trump On Another ACA Repeal Rampage
Leave it to Donald Trump. The former president went to Truth Social again to say he wants to repeal the Affordable Care Act (ACA). This led to yet more consternation and efforts to downplay the call by Republican lawmakers. On Christmas Day, Trump again said he would replace the ACA with a “much better” alternative. ““Obamacare is too expensive, and otherwise, not good healthcare,” he added. “I will come up with a much better, and less expensive, alternative! People will be happy, not sad!”, he ended. The problem is he and the GOP have never come up with a credible alternative.
#aca #exchanges #medicaid #obamacare #coverage #healthcare #healthcarereform
Bristol Myers Squibb Buying Cancer Treatment Entity
Bristol Myers Squibb announced a deal to acquire RayzeBio in a $4.1 billion deal. Larger drug makers are increasingly buying promising firms to bolster its lagging pipeline and to make up for expiring patents.
#branddrugmakers #drugpricing
— Marc S. Ryan
